keyword
MENU ▼
Read by QxMD icon Read
search

Folfox

keyword
https://www.readbyqxmd.com/read/28426267/a-phase-2-trial-of-single-agent-axitinib-as-maintenance-therapy-following-first-line-treatment-with-modified-folfox-bevacizumab-in-patients-with-metastatic-colorectal-cancer
#1
Johanna C Bendell, Mathew Joseph, Kirk Barnes, Mark Mainwaring, Dianna Shipley, Chandra Reddy, Laura Blakely, Ronald Blachly, Cassie M Lane, Chris Earwood, Michel Kuzur
This phase-2 trial evaluated the efficacy of axitinib as maintenance therapy for patients with metastatic colorectal cancer (mCRC) following first-line treatment with FOLFOX/bevacizumab. Patients with mCRC received mFOLFOX/bevacizumab followed by axitinib maintenance after four cycles. The primary endpoint was progression-free survival (PFS). Seventy patients were enrolled. Common treatment-related toxicities were fatigue, nausea, diarrhea, and peripheral neuropathy during FOLFOX/bevacizumab treatment; and fatigue, hypertension, diarrhea, and peripheral neuropathy during axitinib treatment...
April 20, 2017: Cancer Investigation
https://www.readbyqxmd.com/read/28413395/a-case-of-advanced-gastric-cancer-with-para-aortic-lymph-node-metastasis-treated-with-preoperative-folfox-chemotherapy-followed-by-radical-subtotal-gastrectomy-and-d2-lymph-node-dissection
#2
Byoung Jo Suh
We report the case of a 73-year-old female who was diagnosed with advanced gastric cancer. Esophagogastroduodenoscopy was used to diagnose Borrmann type 3 advanced gastric cancer located at the gastric antrum. A biopsy revealed poorly differentiated adenocarcinoma. Abdominopelvic computed tomography (CT) and (18)F-fluorodeoxyglucose positron emission tomography-CT (FDG-PET-CT) scans demonstrated multiple lymph node metastases, including the para-aortic lymph nodes. Systemic chemotherapy with 5-fluoruracil (5-FU), oxaliplatin, and leucovorin (FOLFOX) was initiated...
January 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/28400427/circulating-dna-demonstrates-convergent-evolution-and-common-resistance-mechanisms-during-treatment-of-colorectal-cancer
#3
Alain R Thierry, Brice Pastor, Zhi-Qin Jiang, Anastasia Katsiampoura, Christine Parseghian, Jonathan M Loree, Michael J Overman, Cynthia Sanchez, Safia El Messaoudi, Marc Ychou, Scott Kopetz
Purpose: Liquid biopsies allow the tracking of clonal dynamics and detection of mutations during treatment. <p>Experimental design: We evaluated under blinded conditions the ability of cell free DNA (cfDNA) to detect RAS/BRAF mutations in the plasma of 42 metastatic colorectal cancer patients treated on a phase Ib/II trial of FOLFOX and dasatinib, with or without cetuximab. Results: Prior to treatment, sequencing of archival tissue detected mutations in 25/42 patients (60%), while the cfDNA assay detected mutations in 37/42 patients (88%)...
April 11, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28398406/-cetuximab-in-association-with-an-oxaliplatin-based-chemotherapy-as-first-line-treatment-of-metastatic-colorectal-cancer
#4
Fausto Petrelli, Antonio Ghidini, Alberto Zaniboni
The combination of cetuximab with an oxaliplatin-based chemotherapy is becoming a consolidate standard as first line treatment of metastatic colorectal cancer in RAS wild type patients either in the neoadjuvant setting or in the continuum of care of never resectable disease. Available evidence from clinical trials (not considering regimens containing capecitabine or bolus 5-Fu, as in the COIN and NORDIC study, respectively) has clearly outlined the safety and the efficacy of the combination of FOLFOX and cetuximab...
March 2017: Recenti Progressi in Medicina
https://www.readbyqxmd.com/read/28369355/recent-improvement-of-survival-prognosis-after-pulmonary-metastasectomy-and-advanced-chemotherapy-for-patients-with-colorectal-cancer
#5
Jun Nakajima, Tomohiko Iida, Sakae Okumura, Hirotoshi Horio, Hisao Asamura, Yuichi Ozeki, Norihiko Ikeda, Haruhisa Matsuguma, Masayuki Chida, Hajime Otsuka, Masafumi Kawamura
OBJECTIVES: New chemotherapeutic regimens (i.e. FOLFOX or FOLFIRI with molecular targeted drugs) have improved the prognosis of patients with unresectable or recurrent colorectal cancer. To estimate the prognostic impact of these chemotherapies, we examined the chronological change in survival rates of patients who underwent pulmonary metastasectomy for colorectal cancer metastasis. METHODS: Using a large database, we conducted a retrospective, multi-institutional study to collect data of 1223 eligible patients from 26 institutions who had undergone pulmonary metastasectomy with curative intent...
May 1, 2017: European Journal of Cardio-thoracic Surgery
https://www.readbyqxmd.com/read/28367338/folfox-induced-takotsubo-cardiomyopathy-treated-with-impella-assist-device
#6
Swethika Sundaravel, Abdulah Alrifai, Mohamad Kabach, Waqas Ghumman
Chemotherapy induced cardiotoxicity is becoming increasingly prevalent with several new agents being used recently. The incidence of Takotsubo cardiomyopathy due to 5-fluorouracil based chemotherapeutic regimens like FOLFOX is not uncommon. It is also seen with platinum based chemotherapy. Most of these patients have reversible cardiotoxicity and the cardiac function recovers within a short period with supportive treatment. Here we have a patient who presented with cardiogenic shock after 5 days of receiving FOLFOX regimen for colorectal adenocarcinoma...
2017: Case Reports in Cardiology
https://www.readbyqxmd.com/read/28357089/chromothripsis-and-progression-free-survival-in-metastatic-colorectal-cancer
#7
Elina Skuja, Dagnija Kalniete, Miki Nakazawa-Miklasevica, Zanda Daneberga, Arnis Abolins, Gunta Purkalne, Edvins Miklasevics
Metastatic dissemination of the primary tumor is the major cause of death in colorectal cancer (CRC) patients. Multiple chromosomal breaks and chromothripsis, a phenomenon involving multiple chromosomal fragmentations occurring in a single catastrophic event, are associated with cancer genesis, progression and developing of metastases. The aim of this study was to evaluate the effect of chromothripsis and total breakpoint count (breakpoint instability index) on progression-free survival (PFS). A total of 19 patients with metastatic CRC (mCRC) receiving FOLFOX first-line palliative chemotherapy between August, 2011 and October, 2012 were selected for this study...
February 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28356954/multicenter-phase-ii-study-of-infusional-5-fluorouracil-5-fu-leucovorin-and-oxaliplatin-plus-biweekly-cetuximab-as-first-line-treatment-in-patients-with-metastatic-colorectal-cancer-celine-trial
#8
Masanori Kotake, Toru Aoyama, Yoshinori Munemoto, Kenji Doden, Masato Kataoka, Kenji Kobayashi, Genichi Nishimura, Hidehito Fujita, Keishi Nakamura, Akira Takehara, Chihiro Tanaka, Junichi Sakamoto, Naoki Nagata, Koji Oba, Ken Kondo
The current phase II study investigated the efficacy and safety of biweekly cetuximab combined with standard oxaliplatin-based chemotherapy [infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin (FOLFOX-6)] in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC). Sixty patients with a median age of 64 years (range, 38-82 syears) received a biweekly intravenous infusion of cetuximab (500 mg/m(2) on day 1) followed by FOLFOX-6 (2-hour oxaliplatin 85 mg/m(2) infusion on day 1 in tandem with a 2-h leucovorin 200 mg/m(2) infusion on days 1 and 2, and 5-FU as a 400 mg/m(2) bolus followed by a 46-hour 2,400 mg/m(2) infusion on days 1-3)...
February 2017: Oncology Letters
https://www.readbyqxmd.com/read/28328969/oral-tegafur-uracil-as-metronomic-therapy-following-intravenous-folfox-for-stage-iii-colon-cancer
#9
Wen-Yen Huang, Ching-Liang Ho, Chia-Cheng Lee, Cheng-Wen Hsiao, Chang-Chieh Wu, Shu-Wen Jao, Jen-Fu Yang, Cheng-Hsiang Lo, Jia-Hong Chen
The purpose of this study was to estimate the impact of metronomic therapy with oral tegafur-uracil (UFUR) following an intravenous FOLFOX regimen as surgical adjuvant chemotherapy on the overall survival (OS) and disease-free survival (DFS) of stage III colon cancer patients. From the retrospective database of patients who underwent a surgical resection for colorectal cancer at the Tri-Service General Hospital from October 2008 through December 2014, stage III colon carcinomas treated with radical R0 resection were reviewed...
2017: PloS One
https://www.readbyqxmd.com/read/28328812/overall-survival-of-patients-with-kras-wild-type-tumor-treated-with-folfox-forfiri%C3%A2-cetuximab-as-the-first-line-treatment-for-metastatic-colorectal-cancer-a-meta-analysis
#10
REVIEW
Ya-Fan Yang, Gui-Ying Wang, Jing-Li He, Feng-Peng Wu, Yan-Ni Zhang
The addition of cetuximab to FOLFIRI or FOLFOX as the first-line treatment for metastatic colorectal cancer (mCRC) was shown to reduce the risk of disease progression and increase the chance of response in patients with KRAS wild-type disease. An updated systematic meta-analysis was undertaken to determine the efficacy of cetuximab plus FOLFIRI or FOLFOX.Major databases were searched to identify RCTs investigating wild-type KRAS mCRC after the first-line treatment, and treatment with FOLFOX/FORFIRI ± cetuximab was compared...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28301974/folfox-and-intensified-split-course-chemoradiation-as-initial-treatment-for-rectal-cancer-with-synchronous-metastases
#11
T Bird, M Michael, M Bressel, J Chu, S Chander, P Cooray, J McKendrick, M Jefford, A Heriot, M Steel, T Leong, S Ngan
BACKGROUND: Optimal initial management of rectal carcinoma with synchronous metastases (RCSM) is controversial - both for patients being treated with curative and palliative intent. This study aims to evaluate the use of an upfront treatment strategy combining FOLFOX chemotherapy with split-course pelvic chemoradiation (FOLFOX + CRT) for patients with RCSM. MATERIAL AND METHODS: An analysis of all patients who commenced treatment with FOLFOX + CRT at our institutions between January 2009 and June 2014 was performed...
March 16, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28293087/hepatic-artery-infusion-with-raltitrexed-or-5-fluorouracil-for-colorectal-cancer-liver-metastasis
#12
Jian-Hai Guo, Hang-Yu Zhang, Song Gao, Peng-Jun Zhang, Xiao-Ting Li, Hui Chen, Xiao-Dong Wang, Xu Zhu
AIM: To evaluate the efficiency and safety of hepatic artery infusion chemotherapy (HAIC) using raltitrexed or 5-fluorouracil for colorectal cancer (CRC) liver metastasis (CRCLM). METHODS: A retrospective analysis of patients with unresectable CRCLM who failed systemic chemotherapy and were subsequently treated with HAIC at our institute from May 2013 to April 2015 was performed. A total of 24 patients were treated with 5-fluorouracil, and 18 patients were treated with raltitrexed...
February 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28284575/mfolfox6-plus-panitumumab-versus-5-fu-lv-plus-panitumumab-after-six-cycles-of-frontline-mfolfox6-plus-panitumumab-a-randomized-phase-ii-study-of-patients-with-unresectable-or-advanced-recurrent-ras-wild-type-colorectal-carcinoma-sapphire-study-design-and%C3%A2-rationale
#13
Naoki Nagata, Hideyuki Mishima, Shuichi Kurosawa, Koji Oba, Junichi Sakamoto
BACKGROUND: In Japan, oxaliplatin (OXA)/5-fluorouracil (5-FU)/leucovorin (LV)-the mFOLFOX6 regimen-is the most frequently used first-line chemotherapy backbone for metastatic colorectal cancer. However, peripheral nerve disorders caused by OXA during mFOLFOX6 therapy can decrease patients' quality of life. OXA can be safely discontinued from a FOLFOX regimen after 6 cycles during first-line therapy. Also, for patients who discontinue OXA without having experienced peripheral nerve disorders, reintroducing OXA in the later stages of treatment could remain an option...
March 1, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28284171/molecular-subtypes-of-metastatic-colorectal-cancer-are-associated-with-patient-response-to-irinotecan-based-therapies
#14
M Del Rio, C Mollevi, F Bibeau, N Vie, J Selves, J-F Emile, P Roger, C Gongora, J Robert, N Tubiana-Mathieu, M Ychou, P Martineau
BACKGROUND: Currently, metastatic colorectal cancer is treated as a homogeneous disease and only RAS mutational status has been approved as a negative predictive factor in patients treated with cetuximab. The aim of this study was to evaluate if recently identified molecular subtypes of colon cancer are associated with response of metastatic patients to first-line therapy. PATIENTS AND METHODS: We collected and analysed 143 samples of human colorectal tumours with complete clinical annotations, including the response to treatment...
May 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28280603/family-history-of-colorectal-cancer-and-its-impact-on-survival-in-patients-with-resected-stage-iii-colon-cancer-results-from-ncctg-trial-n0147-alliance
#15
Claire L Jansson-Knodell, Nathan R Foster, Daniel J Sargent, Paul J Limburg, Stephen N Thibodeau, Thomas C Smyrk, Frank A Sinicrope, Balkrishna Jahagirdar, Richard M Goldberg, Steven R Alberts
BACKGROUND: Family history of colon cancer often portends increased risk of disease development; however, the prognostic significance of family history related to disease and survival outcomes is unclear. METHODS: To investigate the relationship between family history of colorectal cancer and survival outcomes in stage III colon cancer patients, a prospective cohort of 1,935 patients with resected stage III colon cancer enrolled in a randomized controlled trial (N0147), comparing the standard of care FOLFOX to FOLFOX with cetuximab, was studied...
February 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28280091/dual-inhibition-of-egfr-and-c-src-by-cetuximab-and-dasatinib-combined-with-folfox-chemotherapy-in-patients-with-metastatic-colorectal-cancer
#16
Christine Parseghian, Nila U Parikh, Ji Yuan Wu, Zhi-Qin Jiang, Laura D Henderson, Feng Tian, Brice Pastor, Marc Ychou, Kanwal Raghav, Arvind Dasari, David Fogelman, Anastasia Katsiampoura, David G Menter, Robert A Wolff, Cathy Eng, Michael J Overman, Alain R Thierry, Gary E Gallick, Scott Kopetz
BACKGROUND: Aberrant activation of the intracellular tyrosine kinase Src has been implicated as a mechanism of acquired chemotherapy resistance in metastatic colorectal cancer (mCRC). Here, the oral tyrosine kinase Src inhibitor, dasatinib, was investigated in combination with FOLFOX and cetuximab. METHODS: We performed a phase IB/II study of 77 patients with previously-treated mCRC. Primary objectives were to determine the MTD, dose-limiting-toxicities, pharmacodynamics, and efficacy...
March 9, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28279170/patients-with-pathological-stage-n2-rectal-cancer-treated-with-early-adjuvant-chemotherapy-have-a-lower-treatment-failure-rate
#17
Yan-Ru Feng, Jing Jin, Hua Ren, Xin Wang, Shu-Lian Wang, Wei-Hu Wang, Yong-Wen Song, Yue-Ping Liu, Yuan Tang, Ning Li, Xin-Fan Liu, Hui Fang, Zi-Hao Yu, Ye-Xiong Li
BACKGROUND: In this era of oxaliplatin-based adjuvant therapy, the optimal sequence in which chemoradiotherapy should be administered for pathological stage N2 rectal cancer is unknown. The aim of this study was to investigate this sequence. METHODS: In the primary adjuvant concurrent chemoradiotherapy (A-CRT) group (n = 71), postoperative concurrent chemoradiotherapy was administered before adjuvant chemotherapy. In the primary adjuvant chemotherapy (A-CT) group (n = 43), postoperative concurrent chemoradiotherapy was administered during or after adjuvant chemotherapy...
March 9, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28277294/observational-cohort-study-of-patients-with-metastatic-colorectal-cancer-initiating-chemotherapy-in-combination-with-bevacizumab-concert
#18
Jaafar Bennouna, Jean-Marc Phelip, Thierry André, Bernard Asselain, Sébastien Koné, Michel Ducreux
BACKGROUND: The CONCERT study (observational cohort study of patients with metastatic colorectal cancer initiating chemotherapy in combination with bevacizumab) aimed to describe patient characteristics, bevacizumab use, its efficacy in terms of progression-free survival (PFS) and overall survival (OS), and its safety in patients with metastatic colorectal cancer (mCRC) treated in daily medical practice. PATIENTS AND METHODS: CONCERT was an observational, prospective, multicenter, cohort study conducted in France...
August 9, 2016: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28275117/randomized-phase-ii-trial-of-parsatuzumab-anti-egfl7-or-placebo-in-combination-with-folfox-and-bevacizumab-for-first-line-metastatic-colorectal-cancer
#19
Rocío García-Carbonero, Eric van Cutsem, Fernando Rivera, Jacek Jassem, Ira Gore, Niall Tebbutt, Fadi Braiteh, Guillem Argiles, Zev A Wainberg, Roel Funke, Maria Anderson, Bruce McCall, Mark Stroh, Eric Wakshull, Priti Hegde, Weilan Ye, Daniel Chen, Ilsung Chang, Ina Rhee, Herbert Hurwitz
LESSONS LEARNED: These negative phase II results for parsatuzumab highlight the challenges of developing an agent intended to enhance the efficacy of vascular endothelial growth factor inhibition without the benefit of validated pharmacodynamic biomarkers or strong predictive biomarker hypotheses.Any further clinical development of anti-EGFL7 is likely to require new mechanistic insights and biomarker development for antiangiogenic agents. BACKGROUND: EGFL7 (epidermal growth factor-like domain 7) is a tumor-enriched vascular extracellular matrix protein that supports endothelial cell survival...
April 2017: Oncologist
https://www.readbyqxmd.com/read/28270172/neoadjuvant-folfox-chemotherapy-combined-with-radiotherapy-followed-by-radical-resection-in-patients-with-locally-advanced-colon-cancer
#20
Chun-Ming Huang, Ming-Yii Huang, Cheng-Jen Ma, Yung -Sung Yeh, Hsiang-Lin Tsai, Ching-Wen Huang, Chih-Jen Huang, Jaw-Yuan Wang
BACKGROUND: Patients with locally advanced colon cancer (LACC) have a relatively poor prognosis despite radical resection and adjuvant chemotherapy. This study investigated the treatment efficacy and toxicity of neoadjuvant chemoradiotherapy in patients with LACC. METHODS: We retrospectively reviewed 36 patients with LACC preoperatively treated with chemotherapy and radiotherapy. Patients were administered chemoradiotherapy, which comprised radiotherapy and neoadjuvant chemotherapy involving a 5-fluorouracil, leucovorin, and oxaliplatin regimen every 2 weeks...
March 7, 2017: Radiation Oncology
keyword
keyword
2273
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"